Last reviewed · How we verify
Methadone group
Methadone, marketed by the Keck School of Medicine of USC, is a well-established drug in the treatment landscape. A key strength is the protection provided by its key composition patent, which expires in 2028. The primary risk is the lack of revenue data, which may indicate limited commercial success or significant competition.
At a glance
| Generic name | Methadone group |
|---|---|
| Also known as | Dose 1, Dose 2, Dose 3 |
| Sponsor | Keck School of Medicine of USC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder (PHASE2)
- Transcranial Magnetic Stimulation for Methadone Maintenance Therapy Combined With Methamphetamine Abuse (NA)
- Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic
- Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK (EARLY_PHASE1)
- Evaluation of Analgesia for Cardiac Elective Surgery in Children (PHASE3)
- Evaluation of Analgesia for Spine Fusion Elective Surgery in Children (PHASE3)
- An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment (PHASE1)
- Divided or Single Exposure (DOSE) Study (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methadone group CI brief — competitive landscape report
- Methadone group updates RSS · CI watch RSS
- Keck School of Medicine of USC portfolio CI